Amgen (AMGN) concluded the recent trading session at $371.47, signifying a +1.48% move from its prior day's close.

By Jonathan Stempel NEW YORK, July 21 (Reuters) - Amgen reached a $74 million settlement of a lawsuit accusing the ...

Amgen has agreed to a $74 million settlement with investors who allege that the company hid a massive U.S. tax bill from the ...

Looking back on therapeutics stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Amgen ...

A recent court decision blocking Colorado’s planned 70% price cap on Enbrel has removed a key regulatory overhang for Amgen ...

Tests found that the foreign matter does not pose a clinical risk to patients.

Amgen said there is no link between its experimental weight loss drug, MariTide, and changes in bone density. The statement comes a day after that potential safety concern wiped off more than $12 ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

Amgen will employ the Veeva Clinical Platform to support and identify efficiencies across the clinical trial process. "We're excited to help Amgen further advance clinical development. Veeva Clinical ...

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...